A Vaccination carried out quickly after exposure to the virus can prevent the disease or make its development less serious, justified the European Commission on Tuesday.
Article written by
Reading time : 1 min.
A new bulk vaccine order in the EU. The European Commission and the Danish laboratory Bavarian Nordic announced on Tuesday 14 June the conclusion of a contract for the purchase of 109,090 doses of monkeypox vaccines. The amount of the transaction was not disclosed.
Marketed under the name Imvanex in Europe, this vaccine has been authorized in Europe since 2013 and is indicated against smallpox in adults. The European medicines regulator has started discussions with Bavarian Nordic to possibly expand its use against monkeypox.
The vaccines will be made available to the Twenty-Seven as well as to Norway and Iceland, with first deliveries by the end of June for priority countries. Some 900 cases have been reported since mid-May in 19 member states as well as Norway and Iceland, according to the Commission.
The European Center for Disease Control and Prevention has recommended early post-exposure vaccination to prevent the disease or make its development less serious, recalls Brussels. This disease is most often benign, but its spread outside endemic areas, mainly in Europe, remains a source of concern. It first results in a high fever and quickly evolves into a rash, with the formation of scabs.